Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance.
about
Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistanceNext-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidencePemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatmentThe enhanced tumor inhibitory effects of gefitinib and L-ascorbic acid combination therapy in non-small cell lung cancer cells.EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer.Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.Usefulness of Bronchoscopic Rebiopsy of Non-Small Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor.Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma.Chemotherapy with or without pemetrexed as second-line regimens for advanced non-small-cell lung cancer patients who have progressed after first-line EGFR TKIs: a systematic review and meta-analysis.
P2860
Q26775379-C9FEEA75-D9C5-46DF-948D-5C4676465D8BQ28079320-CD01D9FE-E1F3-47F0-9FE7-D0081101B73DQ36716210-07B9F74E-5161-43F5-9DC5-64EBC72F761BQ38697702-8E2F88D4-8A1B-4653-9FC8-51305C32857CQ45886897-4632CD89-FE88-4DF3-BD67-00A171514E70Q47814631-0C9E5E83-A496-49CD-8C35-5B5C801B6B62Q52723939-710BD073-F2ED-442A-9822-7A1F35A78366Q53394177-8914CB83-45C1-49C8-971D-CD81ACE08C47Q55484524-67D0FC3B-0371-4F85-BE8D-49FDD3CA5A5A
P2860
Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Clinical approaches to treat p ...... inhibitor acquired resistance.
@en
type
label
Clinical approaches to treat p ...... inhibitor acquired resistance.
@en
prefLabel
Clinical approaches to treat p ...... inhibitor acquired resistance.
@en
P2860
P356
P1476
Clinical approaches to treat p ...... inhibitor acquired resistance
@en
P2093
Rosa Lerose
P2860
P304
P356
10.1177/1753465815587820
P577
2015-05-27T00:00:00Z